Loading...
•
Sep 30
Protalix Q3 2025 Earnings Report
Protalix reported a net income of $2.36 million on revenue of $17.85 million in Q3 2025.
Key Takeaways
Protalix posted a slight revenue decline in Q3 2025 but remained profitable, supported by stable sales across its partners and increased R&D investments.
Revenue for Q3 2025 was $17.85 million, down 1% from the same quarter last year.
Net income for the quarter was $2.36 million, or $0.03 per share (basic and diluted).
Sales were led by $8.8M from Chiesi, $6.1M from Fiocruz (Brazil), and $2.8M from Pfizer.
R&D expenses increased to $4.5 million, driven by phase 2 trial preparations for PRX-115.
Protalix
Protalix
Protalix Revenue by Segment
Protalix Revenue by Geographic Location
Revenue by Segment
Goods Sales Revenue
CapyFin.comLicense & R&D Revenue
CapyFin.comRevenue by Geographic Location
Pfizer Revenue
CapyFin.comFiocruz (Brazil) Revenue
CapyFin.comChiesi Revenue
CapyFin.com Forward Guidance
Protalix expects continued investment in R&D for PRX-115 and modest revenues from license activities as Elfabrio development concludes.
Positive Outlook
- IND submission for PRX-115 Phase 2 trial approved by FDA.
- Stable product sales across all major partners.
- Cash and deposits total $29.4M, supporting operations for at least 12 months.
- Financial position strengthened with year-over-year decline in SG&A.
- Ongoing regulatory efforts to expand dosing options for Elfabrio in EU.
Challenges Ahead
- Quarterly revenue decreased slightly YoY despite stable sales volumes.
- Increased R&D costs may pressure margins in upcoming quarters.
- License & R&D revenue contribution remains minimal.
- Uncertainty surrounding EMA’s opinion on Elfabrio’s E4W regimen.
- Market volatility due to geopolitical risks and EU regulatory setbacks.